Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient
Jan 11, 2019
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.